Articles related to Cardiology, Interventional
Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update
A layered approach to care is described with lifestyle interventions being a key feature of the updated recommendations. The recommendations now include therapies proven to improve cardiovascular and kidney outcomes in patients with diabetes and CKD.
Cardiology January 19th 2023
Damar Hamlin’s Cardiac Arrest: A Cardiologist’s Perspective
Commotio cordis — cardiac arrest after a blunt force trauma to the chest — is thought to occur because a hard object strikes the chest in a vulnerable moment in the cardiac cycle, setting off ventricular fibrillation. The rare condition has been described with a ball strike to the chest, but primarily in young men whose chests haven’t fully developed, making them more susceptible to the blunt force of a ball.
Cardiology January 10th 2023
Can Weightlifting Lower Risk of Death from Cancer and Cardiovascular Disease?
In a study originally published in British Journal of Sports Medicine, a sample of nearly 100,000 adults showed that after making adjustments for other activity, weight training was associated with a 9% decline in CVD mortality. A separate study published in Medicine & Science in Sports & Exercise showed a lower risk of colorectal cancer in adults who lifted weights.
Cardiology November 28th 2022
Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients with Atrial Fibrillation
Medical records of more than half a million individuals in the EU, UK, and US were evaluated. Apixaban was the most frequently prescribed direct oral anticoagulant (DOAC) for AFib. It was also associated with a lower incidence of GI bleed vs. the other DOACs.
Cardiology November 9th 2022
Alpine Stops Enrollment in Cancer Drug Study After Second Patient Death This Year
According to reports, the second patient who passed away during the Phase 1 test of the cancer drug davoceticept by Alpine Immune Sciences experienced the same cardiovascular issue as the first patient.
Cardiology November 7th 2022
Effect of Ivermectin vs. Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial
The median time to recovery in a group of 1,800 vaccinated and unvaccinated adults (median age: 48 years) was essentially the same whether the patients received ivermectin or placebo: 12 and 13 days, respectively. Death rate was slightly higher in the ivermectin group and rates of pneumonia and VTE were slightly higher in the placebo group.
Allergy & Immunology November 2nd 2022